Takeda's takhzyro® (lanadelumab-flyo) prefilled syringe now available for people with hereditary angioedema (hae) ages 12 years and older in the united states

Cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced takhzyro® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the u.s. to prevent attacks of hereditary angioedema (hae) in adult and pediatric patients 12 years of age and older.1 hae is a rare genetic disease that results in recurrent attacks of edema (swelling) in various parts of the body, which can be burdensome, debilitating and potentially life-threatening.2,3,4 approved by the u.s. f
TAK Ratings Summary
TAK Quant Ranking